Shop peptides →

Research Library  ·  Longevity

The best peptides for anti-aging, honestly ranked.

Five candidates. One has FDA approval. The rest mix legitimate cell-culture evidence with decades of older Russian-language work and real cancer-cell warning signs. Here's the honest picture.

WTBP Research Team May 2026 12 min read 8 cited sources

Anti-aging is the peptide category where the marketing diverges most dramatically from the evidence. We've read the 2026 reviews, the Russian originals, and the 2025 cancer-cell finding nobody talks about. Here's the honest ranking for the best peptides for anti-aging.

Only one peptide here has FDA approval, and SS-31 won it in 2025 for Barth syndrome alone. Oral NMN (a NAD+ precursor) has the strongest human trial evidence, while Epithalon's telomere claims rest almost entirely on one Russian research group. GHK-Cu has decades of topical evidence and almost no systemic human data. IV glutathione has formal FDA warnings.

Aging biology is a real research field. The hallmarks-of-aging framework covers nine pathways: mitochondrial dysfunction, cellular senescence, telomere attrition, epigenetic drift, loss of proteostasis, deregulated nutrient sensing, stem cell exhaustion, altered intercellular signaling, and chronic inflammation. The peptides below intervene at different points in that framework, but with very different evidence depths.

“

Despite frequent appearance in grey-market protocols, robust human clinical evidence for performance, body composition, or musculoskeletal recovery indications for most anti-aging peptides is essentially absent.

— paraphrased framing from the 2026 Mavrych review in Frontiers in Aging

Three reviews anchor this article. The 2026 Mavrych review in Frontiers in Aging surveys peptides in gerontology. The 2025 Araj review summarizes 25 years of Epitalon studies. The 2025 Shirley paper in Drugs documents the SS-31 FDA approval. You'll see them cited throughout.

How anti-aging peptides actually work

The mechanisms cluster into five buckets. We'll keep these short so you can map each peptide back to one.

Where this category falls short. Anti-aging effects in cell culture and rodent models don't consistently translate to human lifespan or healthspan in controlled trials. The peptides below have real mechanistic biology. The published human evidence for life extension is meaningfully thinner than the consumer marketing implies.

Here is the ranked five in one view, before we take each in turn.

Compound Mechanism Best human evidence Status The catch
NAD+ Not a peptide — a dinucleotide coenzyme. Raising NAD+ availability feeds the sirtuins, the NAD+-dependent enzymes that mediate cellular stress responses, and supports redox balance A 2022 GeroScience dose-response trial in 80 middle-aged adults on 300, 600 or 900 mg NMN daily for 60 days — blood NAD+ rose in every dose group and six-minute walking distance improved; a 2024 trial at 250 mg/day showed faster four-meter walking and better sleep Not FDA-approved. The FDA rejected NMN as a dietary supplement in 2022 because it is being investigated as a drug The evidence is for oral precursors, not the IV NAD+ infusions clinics sell; NAD+ is rapidly broken down in plasma, and even the oral gains are modest
Epithalon Four-amino-acid peptide (Ala-Glu-Asp-Gly); claimed telomere maintenance through telomerase activation, observed in cell culture as hTERT mRNA upregulation Not established — zero PubMed-indexed Western randomized trials exist for any indication; the human rationale is short periodic courses from Russian clinical practice Not FDA-approved. Western evidence is cell-culture telomerase activation, with no Western randomized trials A 2025 Brunel University London study documented ALT activation in cancer cells, and telomerase is active in roughly 90% of human cancers, so chronically activating it is theoretically problematic
SS-31 Binds cardiolipin in the inner mitochondrial membrane, stabilizing the cristae, supporting the cardiolipin-cytochrome c supercomplex, reducing oxidative stress and preserving ATP output FDA approval in September 2025 for improving muscle strength in Barth syndrome at ≥30 kg, with a 168-week open-label extension supporting long-term safety FDA-approved as Forzinity (September 2025) for Barth syndrome. Phase III ongoing in mitochondrial myopathy, dry AMD and heart failure The MMPOWER-3 Phase III missed its primary endpoint in unselected mitochondrial myopathy, eight weeks in aged mice improved function without significant change in DNA methylation or transcriptomic age, and grey-market SS-31 isn't the same product as prescription Forzinity
GHK-Cu Copper(II) complex of the endogenous tripeptide glycyl-L-histidyl-L-lysine; tissue remodeling through collagen synthesis, fibroblast stimulation and elastase inhibition (around 49% in vitro) Decades of cosmetic formulation history supporting topical wound healing, collagen stimulation and skin remodeling; the endogenous decline from about 200 ng/mL at age 20 to roughly 80 ng/mL at 60 is a real age-related biomarker Not FDA-approved. Used topically at cosmetic grade (0.05 to 3%); systemic subcutaneous use is grey-market and not validated in human trials Topical evidence does not extrapolate to injectable use — zero PubMed-indexed randomized trials of injectable GHK-Cu in humans exist — and the same STAT3 modulation is relevant to cancer biology
Glutathione Tripeptide (γ-L-glutamyl-L-cysteinyl-glycine) that works as a redox cofactor rather than a signalling peptide, scavenging ROS through its cysteine thiol and serving as a cofactor for glutathione peroxidases A 2021 double-blind trial in 46 participants where topical plus oral GSH lowered melanin index and raised skin lightness versus placebo Not FDA-approved. The US FDA has issued warnings about unapproved IV glutathione products and the Philippines FDA has warned against IV GSH for skin whitening. The precursor NAC is FDA-approved for acetaminophen overdose and as a mucolytic Oral bioavailability is poor because gut peptidases chop the tripeptide before absorption, and IV use for skin whitening has documented serious adverse events including Stevens-Johnson syndrome, hepatotoxicity, anaphylactic reactions and deaths in case reports

1. NAD+: real precursor research, contested IV use

NAD+ isn't a peptide. It's a dinucleotide coenzyme. We're including it because it dominates anti-aging marketing and you'll see it sold in every longevity clinic. NAD+ levels decline with age across most tissues, which has driven enormous interest in “NAD+ boosting.”

The legitimate research has focused on oral precursors. The two that matter are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are vitamin-B3 derivatives that raise NAD+ levels when you swallow them.

A 2022 dose-response trial in GeroScience randomized 80 middle-aged adults to placebo or 300, 600, or 900 mg of NMN daily for 60 days (Yi et al., 2022). Blood NAD+ rose in every dose group. Six-minute walking distance improved. Biological-age scores stayed flat in NMN groups while rising in placebo. SF-36 health scores went up.

A 2024 trial in older adults (Morifuji et al., 2024) at 250 mg/day NMN showed faster four-meter walking times and better sleep quality. That's a real functional gain, but it's modest — you're not getting a decade younger.

Strengths. Real trial evidence base for oral precursors. Functional endpoints like walking speed and sleep quality, not just biomarkers. Mechanism is well-characterized. Well-tolerated up to 900 mg/day. We rank this as the most evidence-supported intervention in the category.

Limitations. The evidence is for oral precursors, not IV NAD+ infusion. Clinics sell IV NAD+ for anti-aging, addiction recovery, and energy with no trial support for those claims. NAD+ is rapidly broken down in plasma. The cellular uptake of intact NAD+ via the SLC12A8 transporter is contested. Even oral evidence shows modest gains, not dramatic anti-aging. The FDA rejected NMN as a dietary supplement in 2022 because it's being investigated as a drug.

2. Epithalon: cell-culture biology, single-source human data

Epithalon (also spelled Epitalon) is a four-amino-acid peptide. Its sequence is Ala-Glu-Asp-Gly, hence the abbreviation AEDG. The Khavinson group in Saint Petersburg synthesized it in the 1980s based on the amino-acid composition of Epithalamin, a bovine pineal extract Russian labs studied since the 1970s.

The mechanism evidence is real, but it's mostly produced by one research consortium. A 2025 Brunel University London study was one of the few non-Khavinson groups to publish. It documented telomere-length extension in normal cells via hTERT mRNA upregulation. It also documented something nobody talks about: ALT activation in cancer cells (Al-Dulaimi et al., 2025). ALT stands for Alternative Lengthening of Telomeres, a backup pathway cancer cells use to keep their telomeres long. That's the finding you won't see in any vendor copy.

Strengths. The molecular biology isn't fictional. Both the Khavinson group and at least one independent Western group have observed telomerase modulation in cell culture. A 2022 Chinese group reported Epithalon reduced ROS and apoptosis in aged mouse oocytes (Yue et al., 2022). A 2025 Italian-Russian collaboration (Gatta et al., 2025) showed it enhanced wound healing in retinal pigment epithelial cells damaged by high glucose.

Limitations. The vast majority of Epithalon research comes from one Russian consortium. Independent Western replication is sparse. Zero PubMed-indexed Western randomized trials exist for any indication. The 2025 ALT finding raises a real concern: telomerase is active in roughly 90% of human cancers, so chronically activating it is theoretically problematic. The “telomere extension” consumer claim rests on cell-culture data, not validated measurements in human telomeres.

3. SS-31: FDA-approved, but for Barth syndrome (not longevity)

SS-31 (also called Elamipretide, sold as Forzinity) is the only FDA-approved peptide on this list. In September 2025, the FDA approved it for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg (Shirley, 2025). Barth syndrome is a rare genetic disorder of cardiolipin metabolism. It is not a longevity indication.

The longevity-relevant mechanism is mitochondrial. SS-31 binds cardiolipin in the inner mitochondrial membrane. That stabilizes the cristae (the folds where energy production happens), supports the cardiolipin-cytochrome c supercomplex, reduces oxidative stress, and preserves ATP output (Tung et al., 2025).

A 2025 Aging Cell paper showed something important. Eight weeks of elamipretide in aged mice reduced frailty, improved cardiac strain, and increased muscle fatigue resistance. But it did not produce statistically significant changes in DNA methylation or transcriptomic age (Mitchell et al., 2025). The authors read this as evidence that age-related functional changes can be uncoupled from molecular biological-age markers. That's a useful caveat for anyone selling “biological age reversal.”

Strengths. The only FDA-approved peptide on this list, with a 168-week open-label extension supporting long-term safety. The most mechanistically distinct compound in the longevity-adjacent space. Cardiolipin binding is unique pharmacology. Improved cardiac and skeletal-muscle function in eight weeks in aged mice.

Limitations. Approved for Barth syndrome, not longevity. The MMPOWER-3 Phase III trial missed its primary endpoint in unselected mitochondrial myopathy (Karaa et al., 2023). The 2025 Aging Cell finding complicates the longevity framing. Grey-market SS-31 isn't the same product as prescription Forzinity. Off-label longevity or athletic use extrapolates well beyond the trial evidence.

4. GHK-Cu: strong topical evidence, thin systemic

GHK-Cu is the copper(II) complex of an endogenous tripeptide called glycyl-L-histidyl-L-lysine. It's a clear case of legitimate biology with thin support for the injectable applications now being marketed. GHK circulates physiologically at about 200 ng/mL at age 20 and drops to roughly 80 ng/mL by age 60 (Dou et al., 2020). That decline is a real age-related biomarker.

The topical evidence is among the strongest of any peptide in this catalog. Decades of cosmetic formulation history support GHK-Cu for wound healing, collagen stimulation, and skin remodeling. Elastase inhibition runs around 49% in vitro (Dymek et al., 2023). A 2025 ulcerative-colitis hydrogel study showed GHK-Cu modulates SIRT1 and STAT3 signaling (two stress-response and inflammation pathways) in colon cells (Mao et al., 2025).

Strengths. Among the most evidence-supported peptides for topical wound healing and skin effects. Real endogenous human peptide that declines with age (a 60% drop from age 20 to 60). Reproducible effects on collagen, fibroblasts, and elastase across multiple independent labs. Decades of cosmetic safety data.

Limitations. Topical evidence does not extrapolate to injectable use. Zero PubMed-indexed randomized trials of injectable GHK-Cu in humans exist for IBD, lung disease, anti-aging, or any other systemic indication. The same STAT3 modulation that's therapeutically interesting in inflammation is relevant to cancer biology too. STAT3 is an oncogenic transcription factor. Grey-market injectable purity is uncertain.

SS-31 research-grade vial — mid-distance view

SS-31 (Elamipretide)

Mitochondrial
Tetrapeptide 4 aa Mitochondria-targeted

The same compound cited across the multiple Phase III trials and FDA approval review in this article. Lab-verified identity and purity.

Shop Epithalon

5. Glutathione: real redox biology, IV-route safety warnings

Glutathione (GSH) is structurally a tripeptide. Its three amino acids are γ-L-glutamyl-L-cysteinyl-glycine. It functions as a redox cofactor, not a signaling peptide. We're including it because it's widely marketed for anti-aging, “detox,” and skin-brightening claims.

The redox biology is real. Oral GSH has poor bioavailability. IV GSH carries documented serious safety concerns. That's the honest summary.

The mechanism: GSH directly scavenges ROS through its cysteine thiol. It serves as a cofactor for glutathione peroxidases (enzymes that reduce hydrogen peroxide and lipid peroxides). It also conjugates with electrophiles to help the body detoxify xenobiotics. The pharmacokinetic problem is that gut peptidases (specifically γ-glutamyltransferase) chop up the tripeptide before you absorb it. The body makes its own GSH from cysteine, glutamate, and glycine, with cysteine as the rate-limiting building block. That makes N-acetylcysteine (NAC) the more bioavailable practical precursor.

Strengths. Real redox biology with well-characterized cellular function. A 2021 double-blind trial in 46 participants showed topical plus oral GSH lowered melanin index and raised skin lightness vs placebo (Wahab et al., 2021). NAC is FDA-approved for acetaminophen overdose and as a mucolytic. The tyrosinase-inhibition mechanism for skin tone is real.

Limitations. Oral GSH bioavailability is poor. Intracellular GSH rises more efficiently from NAC. IV glutathione for skin whitening has documented serious adverse events including Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatotoxicity, nephrotoxicity, anaphylactic reactions, and deaths in case reports. The Philippines FDA has issued formal warnings against IV GSH for skin whitening. The US FDA has issued warnings about unapproved IV glutathione products.

Adjacent / support peptides

MOTS-c: the mitochondrial-derived peptide

MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene. It's one of a small class of peptides made inside mitochondria rather than the cell nucleus. Preclinical work shows AMPK activation (AMPK is an energy-sensing enzyme), insulin sensitivity improvement, and exercise-mimetic effects. The mechanism is reasonable. Human trial data is limited. It's currently out of stock in our catalog as of May 2026.

5-Amino-1MQ: the NNMT-inhibitor small molecule

5-Amino-1MQ is a small molecule, not a peptide. It inhibits NNMT, an enzyme that depletes intracellular NAD+ in fat tissue. Preclinical obesity and muscle-function work is encouraging. Human trial data is absent. The mechanism differs from oral NMN.

Optimal stacking protocols

Oral NMN plus topical GHK-Cu

This is the most evidence-supported anti-aging stack. Oral NMN at 250 to 600 mg/day matches the Yi 2022 and Morifuji 2024 trial doses. Topical GHK-Cu in a liposomal or hyaluronic-acid carrier handles skin aging. Each compound uses the route with the cleanest evidence: oral for NMN, topical for GHK-Cu. The risk profile is the lowest in this list.

The mitochondrial stack: SS-31 plus NAD+

Prescription SS-31 (Forzinity) under medical supervision for Barth syndrome plus oral NMN as sirtuin substrate. Both interventions target mitochondrial function through different mechanisms: cardiolipin stabilization plus NAD+ availability for SIRT3, the mitochondrial deacetylase. Off-label SS-31 longevity use isn't evidence-supported. The prescription product is meaningfully different from grey-market SS-31.

The cell-culture caveat stack: Epithalon

Epithalon 5 to 10 mg daily for 10 to 20 days every 6 to 12 months is the grey-market consensus. It's based on Khavinson clinical practice, not Western trials. The 2025 Brunel ALT-activation finding is the critical context anyone considering chronic telomerase activation should weigh. This stack has high marketing volume and low evidence volume.

Training, nutrition, lifestyle considerations

The hallmarks-of-aging framework these peptides target is responsive to lifestyle interventions with stronger evidence than any peptide on this list. Caloric restriction, time-restricted eating, regular resistance training, cardiovascular fitness, sleep quality, social connection, and stress management all have published evidence for healthspan and lifespan in human populations. Some effect sizes exceed what any current peptide intervention matches.

Here's the honest framing. These compounds intervene at specific molecular hallmarks. The molecular hallmarks sit downstream of the systems-level processes lifestyle interventions modify: mitochondrial health, inflammation, glucose homeostasis, sleep quality. Peptides without lifestyle adequacy have weaker pharmacological signal than peptides paired with strong lifestyle foundations.

GHK-Cu research-grade vial

GHK-Cu

Tissue / Copper Biology
50 mg ≥99% pure Copper-bound tripeptide

Endogenous human tripeptide-copper complex with decades of topical formulation history. The same reference compound used across the cited preclinical and clinical studies. COA available with each lot.

Learn more

Safety, monitoring, legal status

Required monitoring

You'll want a baseline metabolic panel, fasting glucose, lipid panel, and complete blood count before starting anything systemic. For telomerase activators like Epithalon, add age-appropriate baseline cancer screening. The theoretical cancer concern from chronic telomerase activation is real enough to warrant it. For SS-31 used as prescribed Forzinity, standard pharmaceutical monitoring with cardiac and skeletal-muscle endpoints applies.

Known risks

Cancer-cell ALT activation has been documented for Epithalon in vitro. That's the basis for the theoretical concern about pro-cancer effects in someone with an undiagnosed malignancy. IV NAD+ produces substantial flush reactions including chest tightness, facial flushing, and anxiety. It requires multi-hour slow administration. IV glutathione for skin whitening has FDA warnings and documented Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, and deaths. The 2026 Mavrych review notes that the grey-market peptide supply chain creates documented risks separate from the molecules themselves.

Legal and regulatory

SS-31 / Elamipretide (Forzinity): FDA-approved September 2025 for Barth syndrome. NMN: rejected as a dietary supplement by the FDA in 2022. NR: sold as a dietary supplement. IV NAD+: no FDA approval. Oral GSH: sold as a dietary supplement. IV GSH: FDA warnings against unapproved use, particularly for skin whitening. Epithalon: not FDA-approved. Used clinically in Russia under Russian regulation. GHK-Cu: not approved as a therapeutic. Used as a cosmetic ingredient under cosmetic regulations.

What to know now

What we're watching

Three things to track over the next 18 months. First, the NuPOWER Phase III readout for SS-31 in mtDNA-replisome primary mitochondrial myopathy. If the genotype-specific responder hypothesis from the MMPOWER-3 post-hoc analysis holds up prospectively, the mitochondrial-recovery use case strengthens substantially. Second, whether any independent Western group attempts to replicate the Khavinson Epithalon findings in a human trial. The authorship-concentration concern is the field's largest methodological gap. Third, whether ChromaDex's long-term NR studies continue showing modest but real functional improvements in older adults. Oral NAD+ precursor evidence is the most likely category to mature into clinical guidelines.

Frequently asked questions

Which anti-aging peptide has the most evidence? Oral NAD+ precursors (NMN and NR) have the most rigorous human trial evidence in this category. Multiple peer-reviewed trials show measurable functional improvements in walking speed, grip strength, and sleep quality at well-tolerated doses. The functional effects are modest. They aren't the dramatic life-extension claims in consumer marketing.

Is IV NAD+ better than oral NMN? The published evidence doesn't support that. NAD+ is rapidly degraded in plasma. Cellular uptake of intact NAD+ is contested in the literature. Oral NMN and NR have trial support for measurable functional endpoints. IV NAD+ doesn't. IV infusions are expensive, uncomfortable, and lack supportive trials for the marketed indications.

Does Epithalon really extend telomeres? In cell culture, yes. Both the Khavinson group and the 2025 Brunel study documented telomere extension via hTERT/telomerase upregulation in normal cells. In humans, the “telomere extension” claim rests on cell-culture data and Russian-language clinical reports, not Western trial validation. The 2025 Brunel finding that Epithalon activates ALT in cancer cells adds an important safety caveat.

Should you worry about cancer risk from Epithalon? The theoretical concern is real. Telomerase is upregulated in approximately 90% of human cancers. Chronic exogenous telomerase activation in someone with an undiagnosed malignancy is theoretically problematic. The Khavinson group argues normal-cell-specific effects mitigate this concern. The 2025 Brunel study showed Epithalon also activates ALT in cancer cells. Pre-treatment cancer screening is prudent.

Is SS-31 a longevity peptide? Not officially. The FDA approved it in September 2025 for Barth syndrome only. Preclinical work in aged mice showed functional improvements in cardiac and skeletal muscle without changes in epigenetic or transcriptomic age. That suggests functional changes can be uncoupled from molecular biological-age markers. Off-label longevity use extrapolates well beyond the trial evidence.

Can you use IV glutathione for skin brightening? The Philippines FDA has issued formal warnings against IV GSH for skin whitening. The US FDA has issued warnings about unapproved IV glutathione products. Documented adverse events include Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatotoxicity, nephrotoxicity, anaphylactic reactions, and deaths in case reports. Cosmetic skin-whitening use sits entirely outside any approved indication.

What's the difference between GHK-Cu topical and injectable? GHK-Cu has decades of topical cosmetic history with documented effects on collagen, fibroblasts, and skin remodeling. Injectable systemic GHK-Cu has no PubMed-indexed randomized trials for any indication. Topical evidence doesn't extrapolate to injectable use.

Will any of these peptides actually extend your lifespan? No peptide has been shown to extend human lifespan in a randomized trial. The hallmarks-of-aging framework these compounds target is responsive to lifestyle interventions, including caloric restriction, exercise, sleep, and social connection, with stronger evidence than any peptide intervention. Honest framing: peptides are pharmacological adjuncts to lifestyle-driven aging-biology optimization, not stand-alone longevity drugs.

References

  1. Yi, L., Maier, A. B., Tao, R., et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45(1), 29–43. https://doi.org/10.1007/s11357-022-00705-1
  2. Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), 178. https://doi.org/10.1007/s10522-025-10315-x
  3. Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691
  4. Shirley, M. (2025). Elamipretide: First Approval. Drugs, 86(3), 377–383. https://doi.org/10.1007/s40265-025-02269-8
  5. Mitchell, W., Pharaoh, G., Tyshkovskiy, A., et al. (2025). The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell, 24(6), e70026. https://doi.org/10.1111/acel.70026
  6. Dou, Y., Lee, A., Zhu, L., et al. (2020). The potential of GHK as an anti-aging peptide. Aging Pathobiology and Therapeutics, 2(1), 58–61. https://doi.org/10.31491/apt.2020.03.014
  7. Wahab, S., Anwar, A. I., Zainuddin, A. N., et al. (2021). Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial. International Journal of Dermatology, 60(8), 1013–1018. https://doi.org/10.1111/ijd.15573
  8. Mavrych, V., Shypilova, I., & Bolgova, O. (2026). Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in Aging, 7, 1790247. https://doi.org/10.3389/fragi.2026.1790247

every peptide, every supplier question, one library.

Browse peptides A–Z How to pick a supplier